"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 3 | 3 |
| 2000 | 4 | 2 | 6 |
| 2001 | 2 | 5 | 7 |
| 2002 | 5 | 6 | 11 |
| 2003 | 4 | 5 | 9 |
| 2004 | 4 | 3 | 7 |
| 2005 | 6 | 2 | 8 |
| 2006 | 2 | 2 | 4 |
| 2007 | 3 | 3 | 6 |
| 2008 | 3 | 6 | 9 |
| 2009 | 12 | 7 | 19 |
| 2010 | 8 | 7 | 15 |
| 2011 | 8 | 7 | 15 |
| 2012 | 3 | 10 | 13 |
| 2013 | 10 | 7 | 17 |
| 2014 | 17 | 11 | 28 |
| 2015 | 7 | 5 | 12 |
| 2016 | 12 | 7 | 19 |
| 2017 | 18 | 13 | 31 |
| 2018 | 19 | 14 | 33 |
| 2019 | 14 | 14 | 28 |
| 2020 | 24 | 15 | 39 |
| 2021 | 15 | 22 | 37 |
| 2022 | 2 | 33 | 35 |
| 2023 | 3 | 19 | 22 |
| 2024 | 12 | 18 | 30 |
| 2025 | 19 | 7 | 26 |
| 2026 | 6 | 9 | 15 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Nanomedicine beyond carriers - devices, cells & living therapeutics. Biomed Microdevices. 2026 Sep 08; 28(3).
-
Case Report: Primed dendritic cell immunotherapy for multiple solid tumors. Front Immunol. 2026; 17:1886898.
-
Lymph nodes now optional. Science. 2026 Jul 16; 393(6808):242-243.
-
Front-line chemo-immunotherapy for advanced penile cancer: ready for prime time? Br J Cancer. 2026 10; 135(7):1019-1021.
-
Evaluating mesothelin as an immunotherapeutic target for endogenous T cells. Front Immunol. 2026; 17:1853409.
-
Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity. Med. 2026 Jul 10; 7(7):101149.
-
Immunotherapies for NORSE and FIRES. Semin Pediatr Neurol. 2026 Oct; 59:101295.
-
Biodegradable nanofibrous drug-eluting seed for sustained intratumoral immunotherapy. J Control Release. 2026 07 10; 395:115004.
-
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases. J Immunother Cancer. 2026 May 04; 14(5).
-
Oncolytic viruses and cytokine-based gene therapies reprogram the tumor microenvironment. Nat Cancer. 2026 May; 7(5):723-739.